Remove Bioavailability Remove Clinical Development Remove Marketing Remove Medicine
article thumbnail

Zerion and Insud to develop Dispersome formulations of drugs

Pharmaceutical Technology

Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.

article thumbnail

Skin Cancer Awareness Month 2024 and Insights from Medicus Pharma

XTalks

Innovations in Skin Cancer Treatment: Precision Medicine and Immunotherapy Treatment options for skin cancer have considerably evolved with a growing emphasis on precision medicine and immunotherapy. Precision medicine allows more effective and personalized treatment plans, which minimizes side effects and improves patient outcomes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally-bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. Development of molnupiravir is entirely funded by Ridgeback Biotherapeutics and Merck & Co.,

Trials 69
article thumbnail

A Complex Chromosomal Abberation Called Adrenoleukodystrophy

Delveinsight

The global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 In patients with CALD, Adrenoleukodystrophy market offers two therapies, namely Lorenzo’s oil and haematopoietic stem cell transplantation (HSCT) , using either umbilical cord stem cells or bone marrow stem cells.

article thumbnail

Sosei Heptares’ COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development

The Pharma Data

These compounds have demonstrated high potency in inhibiting the activity of the M pro protease as well as promising oral bioavailability and blood plasma levels in animal studies. Several compounds are being further optimized for preclinical studies. Details can be found at this link.

article thumbnail

Moving off the critical path: Streamlining strategies for drug substance synthesis and manufacturing

Pharmaceutical Technology

Placing traditionally siloed drug substance and drug product development activities within a single organization that also has commercial manufacturing capabilities accelerates clinical development and builds in quality and robustness of supply. Streamlined processes to reduce time to market for drugs.